Phosphorylated Aryl TEAD Binders for Blocking YAP-TEAD Transcription
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The Hippo signaling pathway lacks druggable targets and ideal small molecule binding sites, making it difficult to develop effective drugs that inhibit YAP-TEAD interaction and transcriptional activity, which are associated with various diseases.
Innovation Solution
Development of small molecule compounds with phosphorylated aryl structures that target the palmitoyl pocket of TEAD, inhibiting YAP-TEAD binding and blocking transcriptional activity, thereby regulating the Hippo signaling pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional small molecule kinase inhibitor strategies are used to target the Hippo signaling pathway, then the pathway can be inhibited, but the approach is theoretically flawed and unsuitable as a drug target because the kinase module negatively regulates transcriptional output
Solution Approach 1:
Instead of inhibiting the kinase module (LATS1/2) that negatively regulates YAP/TAZ, the patent inverts the approach by targeting the transcription factor TEAD directly. Small molecules bind to the palmitoyl pocket of TEAD to block its interaction with YAP/TAZ, thereby inhibiting transcriptional output without interfering with the kinase module's negative regulation. This inversion resolves the theoretical flaw by making TEAD the drug target rather than the kinase.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that bind to the palmitoyl pocket of TEAD. These compounds act as mediators to disrupt the YAP-TEAD interaction, preventing transcriptional activation without directly inhibiting the kinase module. The small molecules serve as the intermediary agent that translates the conceptual shift into a practical drug mechanism.
2Reliability
If small molecule compounds are developed to block Hippo signaling output, then transcriptional activity can be inhibited, but the compounds have poor biological activity and pharmacokinetic properties due to lack of druggable targets
Solution Approach 1:
The patent applies local quality by focusing on a specific functional region of TEAD - the palmitoyl pocket - rather than attempting to target the entire protein. The palmitoyl pocket has distinct structural features (hydrophobic cavity and hydrophilic branch pocket) that are optimized for small molecule binding. This localized targeting approach provides a well-defined binding site with appropriate chemical properties, resolving the issue of poor binding site availability while maintaining high biological activity.
Solution Approach 2:
The patent utilizes parameter changes by designing small molecules with specific physicochemical properties that match the palmitoyl pocket environment. The compounds feature hydrophobic regions to interact with the hydrophobic cavity and hydrophilic regions for the hydrophilic branch pocket, optimizing binding affinity and pharmacokinetic properties. This parameter optimization resolves the contradiction between binding site availability and biological activity.
3Reliability
If YAP-TEAD binding is inhibited to treat diseases, then transcriptional activity is blocked, but existing approaches have unclear mechanisms and poor pharmacokinetic properties
Solution Approach 1:
The patent extracts the palmitoyl group from the TEAD protein structure to identify the palmitoyl pocket as a discrete, druggable target. By focusing on this specific structural element that is normally involved in YAP binding, the patent creates a clear mechanistic basis for small molecule intervention. The extracted palmitoyl pocket serves as a well-defined binding site, providing mechanistic clarity that was previously absent in Hippo pathway targeting approaches.
Data Source
AI summary
The present application discloses a small molecule compound having a phosphorylated aromatic structure and application thereof. The compound and pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof provided in the present application or the pharmaceutical composition provided in the second aspect of the present invention, by targeting the TEAD palmitoyl pocket, effectively inhibits/blocks YAP-TEAD binding, inhibits/blocks the transcription function of YAP-TEAD, thereby preventing and/or treating diseases related to increased TEAD transcription levels and/or YAP phosphorylation disorders and/or Hippo signaling pathway disorders.